Acute Effects of Exercise in Smokers With Schizophrenia

Status Completed

Clinical Trial Summary

People with schizophrenia have two- to three-times the mortality risk of the general population. This is primarily due to their unusually high rates of cigarette smoking, as well as other cardiovascular risk factors such as physical inactivity, obesity, high blood cholesterol and diabetes. Effective smoking treatments are needed to reduce morbidity and mortality in this population. Over a dozen experimental studies indicate that walking and other forms of exercise acutely reduce cigarette craving, nicotine withdrawal symptoms and smoking behavior in non-psychiatric smokers. However, the effects of acute exercise on smoking measures have not been studied in smokers with schizophrenia. This study will use a within-subjects, repeated-measures design, in which participants will undergo 4 laboratory sessions (order counterbalanced across participants): (1) smoking cues followed by exercise, (2) smoking cues followed by passive activity, (3) neutral cues followed by exercise, (4) neutral cues followed by passive activity. Outcome measures include cigarette craving, nicotine withdrawal symptoms, mood and smoking behavior. If the results of this study indicate that walking acutely reduces craving and smoking in smokers with schizophrenia, the next step in this research would be to test the effectiveness of a smoking cessation intervention that incorporates exercise bouts as a behavioral strategy for improving smoking cessation rates in this population.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01635075
Study type	Interventional
Source	Brown University
Contact
Status	Completed
Phase	Phase 2
Start date	June 2012
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01928719` - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status	N/A
Completed	`NCT01995123` - Behavioral Activation for Smoking Cessation in PTSD	N/A
Not yet recruiting	`NCT03249428` - E-Cigarette Inner City RCT	N/A
Recruiting	`NCT02564289` - Cardiovascular Effects of Chronic Snus Use	N/A
Completed	`NCT01928758` - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Completed	`NCT01570595` - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV	Phase 1/Phase 2
Completed	`NCT01428310` - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke	Phase 1
Recruiting	`NCT00977249` - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users	Phase 2/Phase 3
Active, not recruiting	`NCT00968513` - Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry	Phase 3
Completed	`NCT00747643` - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement	N/A
Completed	`NCT01113424` - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum	N/A
Completed	`NCT00722124` - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Phase 2/Phase 3
Completed	`NCT01228617` - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products	N/A
Completed	`NCT01238627` - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg	N/A
Completed	`NCT00296647` - Smoking Cessation Intervention: Effectiveness in Primary Care	Phase 4
Completed	`NCT00394420` - Emergency Department Telephone Quitline	N/A
Recruiting	`NCT05487807` - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia	Phase 1
Completed	`NCT03553992` - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers	N/A
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A